文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 自然科学 > 生物学 > Influenza A H1N1 2009 vaccine in juvenile dermatomyositis reduced immunogenicity in patients under
侵权投诉

Influenza A H1N1 2009 vaccine in juvenile dermatomyositis reduced immunogenicity in patients under

Influenza A H1N1 2009 vaccine in juvenile dermatomyositis reduced immunogenicity in patients under immunosuppressive therapy

adverse event was observed, as also re-ported of JDM patients that received in uenza previously in a limited number vaccine (11, 12). In our large study with 237 diseases pediatric more patients to healthy controls (13).

frequently patients, autoimmune observed, only arthralgia rheumatic comparing was Notably, cines to be licensed, all children, ado-for pandemic in uenza vac-lescents and adults must meet all three current lished: immunologic standards estab->70%, seroconversion >40%, and a fac-a percentage of seroprotection tor increase in GMT >2.5 (29-31). patients and healthy controls evaluated JDM herein ful lled all of the three criteria, indicating that the vaccine, while being less immunogenic, was effective.

In conclusion, this study identi ed that in JDM patients, chronic course and im-munosuppressive seroconversion, suggesting that a specif-therapy may hamper ic vaccination protocol may be required for this subgroup of patients. In spite of that, a single dose of non-adjuvanted in- uenza A H1N1/2009 vaccine was gen-erally seroprotective and had no evident deleterious effect in disease itself.Acknowledgments

We thank the subjects for their critical roles in this study, the staff of Hospital das Investigação Médica (LIM-17), Facul-Clinicas FMUSP, Laboratorio de dade de Medicina da USP, Adolfo Lutz Institute and Butantan Institute.

1. References

SATO A Brazilian registry of juvenile dermatomy-JO, SALLUM AM, FERRIANI VP et al.:

ositis: onset features and classi cation of 189 2. cases. GUSEINOVClin Exp RheumatolalA D, CONSOLARO A, 2009; 27: 1031-8.TRAIL L et

therapies among European and Latin Ameri-.: Comparison of clinical features and drug can patients with juvenile dermatomyositis. 3. Clin Exp RheumatolRAMARTINI VELLI A, LATTANZI 2011; 29: 117-24.

B, rheumatology. A: Glucocorticoids CONSOLARO A,

Clin Exp Rheumatolin paediatric 4. 148-52.

2011; 29: GUTIÉRREZ-SUÁREZ RR, BURGOS-VARGAS

rheumatic : The use of methotrexate in children with diseases. Clin Exp Rheumatol 5. 2010; 28: 122-7.

SILVVaccination A CA, TERRERI matic disease. practice MT, AIKAWA Rev Bras Reumatolin children with NE et al.:

2010; 50: rheu- 6. 351-61.

GLÜCK T, MÜLLER-LADNER U: Vaccination

in patients with chronic rheumatic or autoim-mune diseases. Clin Infect Dis 2008; 46: 7. 1459-65.

MARIE Infectious complications in polymyositis and I, MÉNARD JF, HACHULLA E et al.:

dermatomyositis: a series of 279 8. Semin Arthritis RheumHEIJSTEK et MW, OTT DE 2011; 41: 48-60.

patients. nation in paediatric patients with rheumatic al.: EULAR recommendations BRUIN LM, for BIJL vacci-M

9. diseases. FIORE Ann Rheum Dis 2011; 70: 1704-12.Centers AE, UYEKI TM, BRODER K et al.:

(CDC). for with Prevention Disease and Control control and Prevention visory Committee on Immunization Practices vaccines: recommendations of of in uenza the Ad-(ACIP), 59:1-62. 2010. 2010; 59: 1147. [Erratum, MMWR MMWR Recomm RepMMWR Recomm Recomm Rep 2010; 2010; Rep 10. 59: 993].

CENTERS FOR DISEASE CONTROL AND PRE-VENTION (CDC)United 2010. MMWR Morb Mortal Wkly. Rep States, August : Update: in uenza activity-30, 2009-January 9, 11. 59: 38-43.

2010; OGIMI TC, TANAKA R, SAITOH A, Children With Pediatric Rheumatic Diseases : Immunogenicity of In uenza Vaccine OH-ISHI

in Receiving Immunosuppressive Agents. 12. atr Infect Dis JKANAKOUDI-TSAKALIDOU F, TRACHANA M, 2011; 30: 208-11.

Pedi-PRATSIDOU-GERTSI P, TSITSAMI E, KYRIAZ-in OPOULOU-DALAINA V: In uenza vaccination

and children long-term with immunosuppressive chronic rheumatic diseases therapy. 13. Clin Exp RheumatolAIKAWA 2001; 19: 589-94.

Glucocorticoid: major factor for reduced im-NE, CAMPOS LM, SILVA CA et al.:

munogenicity vaccine of 2009 in uenza A (H1N1) disease patients. in juvenile autoimmune rheumatic 14. 73.

J Rheumatol 2012; 39: 167-COOK IFmunity with human vaccines. : Sexual dimorphism of humoral im-Vaccine 2008; 15. 26: 3551-5.

OH CE, LEE J, KANG JHmunogenicity et al.: Safety and im-in uenza of an inactivated split-virus dren prospective, from A/H1N1 6 months vaccine in healthy chil-open-label, to <18 multi-center years of age: a 16. Vaccinetrial. LIANG XF, WANG HQ, WANG JZ 2010; 28: 5857-63.

and immunogenicity of 2009 pandemic in u- et al.: Safety

enza A H1N1 vaccines in China: a multicen-tre, double-blind, randomised, placebo-con-17. trolled trial. BORBA In uenza EF, Lancet SAAD 2010; 375: 56-66.

CG, PASOTO SG et al.: with SLE: can antimalarial drugs restore di-A/H1N1 vaccination of patients

minished response under immunosuppressive 18. therapy? ABU-SHAKRA Rheumatologypatients with systemic lupus erythematosusM: Safety 2012; 51: 1061-9.of vaccination of

19. LupusBOHAN A, PETER JB 2009; 18: 1205-8.

. 20. omyositis. KENDAL AP, PEREIRA MS, SKEHEL JJN Engl J Med: Polymyositis and dermat- 1975; 292: 344-7.cepts and procedures from laboratory-based : Con-in uenza surveillance. Atlanta: Centers 21. Disease Control and Prevention, 1982.

for BODE ML, LECHMAN RK, KLEIN-GITELMAN TS, PACHMAN MS, LM: MILLER

Disease

588

activity score for children with juvenile der-matomyositis: 22. LOVELL dence. Arthritis Rheumreliability 2003; 49: 7-15.

and validity evi-RMactivity et al.: Development of validated disease DJ, LINDSLEY CB, RENNEBOHM

nile The idiopathic and damage in ammatory indices myopathies. for the juve-(CMAS): a quantitative tool for the evaluation Childhood Myositis Assessment Scale II. of muscle function. The Juvenile Dermatomy-ositis Disease 23. Group. RIDER Arthritis RheumActivity Collaborative Study Validation LG, KOZIOL D, 1999; 42: 2213-9. subset of eight muscles for adult and juvenile of manual muscle GIANNINI testing EH et and al.:

a idiopathic in ammatory myopathies. 24. tis Care ResSPENCER BERNSTEIN BH, KORNREICH HK, KING KKCH, 2010; 62: 465-72.

Arthri-HANSON V, SINGSEN BH,

: 25. J PediatrSHOENFELD 1984; 105: 399-408.

autoimmune/in ammatory syndrome induced Y, AGMON-LEVIN N: ‘ASIA’ –

26. by adjuvants. SAAD CG, BORBA EF, AIKAWA NEJ Autoimmun 2011; 36: 4-8. munogenicity adjuvanted and safety of et al.: Im-large cohort in uenza A/H1N1 the vaccine 2009 non-in a 27. eases.of autoimmune rheumatic dis-MALLESON Ann Rheum Dis 2011; 70: 1068-73.DW, children with chronic arthritis: a prospective WEBER PN, JM: In uenza TEKANO immunization JL, SCHEIFELE

in 28. study. HOLVEffect AST A, J Rheumatol cination on antibody responses in quiescent of a second, VAN ASSEN S, 1993; 20: 1769-73.

booster, DE HAAN Ain uenza et al.:vac-

systemic lupus erythematosus: an open, pro-spective, controlled study. Rheumatology 29. 2009; 48: 1294-9.

HOLVStudies AST A, Vto of AN ASSEN S, DE HAAN A et al.:

erythematosus. in uenza cell-mediated vaccination immune Arthritis in Rheumsystemic responses 2009; lupus 60: 30. 2438-47.

KUNISAKI KM, JANOFF ENmunosuppressed populations: a review of in-: In uenza in im-fection vaccine responses. frequency, Lancet Infect Dismorbidity, mortality, 2009; 9: and 31. 493-504.

MATHIAN alinjections .: Factors A, in uencing DEVILLIERS H, KRIVINE A et

(H1N1) of a pandemic the 2009 ef cacy in uenza of two lupus erythematosus. nonadjuvanted Arthritis Rheumvaccine in systemic A 2011; 32. 63: 3502-11.

EMA. EMUROPEAN COMMITTEE FOR PROPRIETARY

structure and content for pandemic In uenza EDICINAL PRODUCTS: Guideline on dossier vaccine (CPMP/VEG/4717/03). marketing authorisation Agency for the Evaluation London: application of European 33. Products, 2004.Medicinal EMA. CPOMMITTEE

FOR PROPRIETARY Mtion of Requirements for In uenza Vaccines. RODUCTS: Note for Guidance on Harmonisa-EDICINAL

London: European Medicines Agency, 1996. 34. (Publication no. CPMP/BWP/214/96).

USFDA. DSEPARTMENT OF HEALTH AND HUMAN

CERVICESSEARCHENTER FOR, FOOD BIOLOGICS AND D RUG ADMINISTRATION, needed to support the licensure of pandemic : Guidance for industry: clinical data

EVALUATION AND RE-in uenza vaccines. May 2007.

上一页第6页

你可能喜欢

热门文档

相关文档

  • Influenza (the flu)

    Influenza (the flu)_英语学习_外语学习_教育专区。流感预防Influenza (the flu) By Salwa Hassan Teama Ain Shams University Difference Between Cold or FLU ...

  • 流感病毒与流感疫苗 - Influenza and Influenza Vaccines

    流感病毒与流感疫苗 - Influenza and Influenza Vaccines_生物学_自然科学_专业资料。流感病毒与流感疫苗 - Influenza and Influenza Vaccines...

  • Influenza

    Influenza (Flu) What Everyone Should Know About Flu and the Flu Vaccine What is the flu? The flu is a contagious respiratory illness caused by ...

  • Influenza

    Influenza Miley ClassB Influenza, commonly referred to as the flu, is an infectious disease caused by RNA viruses of the family Orthomyxoviridae (the ...

  • HOW_TO_PREVENT_INFLUENZA_en_20051028

    Influenza (flu): ? is a highly infectious viral disease caused by various types of influenza viral strains ? Seasonal Influenza In Hong Kong, the ...

  • Influenza

    42页 免费 Influenza 32页 10财富值搜你所想,读你所爱 拒绝盗版,营造绿色文库 如要投诉违规内容,请到百度文库投诉中心;如要提出功能问题或意见建议,请点击...

  • Influenza

    www.themegallery.com Spring - prone diseases Epidemic cerebrospinal meningitis、 、 influenza , mumps and other respiratory diseases流脑、流感、流腮等呼吸道...

  • INFLUENZA-禽流感 - 关于流感

    Summer 2008 Workshop in Biology and Multimedia for High School Teachers INFLUENZA VIRUS: A Model for Learning About Disease Laurie St.Pierre Sandwich High...

  • 分子病毒学1 influenza_virus

    流行性感冒病毒 influenza virus 流行性感冒病毒(influenza virus)简称流感 病毒。按病毒核蛋白(nucleocapside protein,NP) 和基质蛋白(matrix protein, M)分成甲(A)...

  • influenza

    流行性感冒 influenza 定义:流行性感冒简称流感,是 由流行性感冒病毒引起的急性呼 吸道传染病。 特征:病毒极易变异; 传染性强; 全身症状重; 呼吸道症状轻。 ...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email